Literature DB >> 28983643

[Radical prostatectomy in locally advanced prostate cancer].

P Mandel1, D Tilki2, M Graefen2.   

Abstract

BACKGROUND: Due to an inverse stage migration, the proportion of patients with more aggressive and locally advanced prostate cancer (PCa) has increased over the last few years. The natural history in these patients shows a higher risk of local complications and worse oncologic outcome.
OBJECTIVES: To analyze the impact of radical prostatectomy (RP) in patients with locally advanced PCa.
MATERIALS AND METHODS: A review of the literature was performed using PubMed and MEDLINE databases focusing on articles addressing locally advanced PCa.
RESULTS: Current guidelines recommend local therapy in patients with locally advanced PCa among other treatment options. Thereby no strong evidence favoring radiotherapy or RP is present. Compared to patients without local treatment, RP may improve oncologic outcome and decrease the risk of local complications. Due to more difficult surgery and an increased need of multimodal therapy, higher perioperative morbidity and worse functional outcomes compared to patients with localized PCa are reported. No reliable prospective data indicating a widespread use of neoadjuvant treatment exists. Indication for further adjuvant or salvage therapies depends on pathologic results and postoperative course.
CONCLUSIONS: RP is one of the treatment options with good long-term results which can be offered to patients with locally advanced PCa. Nevertheless, patients need to be counselled especially about the worse postoperative functional outcome compared to patients with localized PCa.

Entities:  

Keywords:  Functional outcome; Locally advanced tumor; Oncologic outcome; Perioperative morbidity; Treatment concept, multimodal

Mesh:

Year:  2017        PMID: 28983643     DOI: 10.1007/s00120-017-0512-3

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  48 in total

Review 1.  Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy.

Authors:  Vincenzo Ficarra; Giacomo Novara; Thomas E Ahlering; Anthony Costello; James A Eastham; Markus Graefen; Giorgio Guazzoni; Mani Menon; Alexandre Mottrie; Vipul R Patel; Henk Van der Poel; Raymond C Rosen; Ashutosh K Tewari; Timothy G Wilson; Filiberto Zattoni; Francesco Montorsi
Journal:  Eur Urol       Date:  2012-06-01       Impact factor: 20.096

2.  Nerve-sparing approach during radical prostatectomy is strongly associated with the rate of postoperative urinary continence recovery.

Authors:  Nazareno Suardi; Marco Moschini; Andrea Gallina; Giorgio Gandaglia; Firas Abdollah; Umberto Capitanio; Marco Bianchi; Manuela Tutolo; Niccolò Passoni; Andrea Salonia; Petter Hedlund; Patrizio Rigatti; Francesco Montorsi; Alberto Briganti
Journal:  BJU Int       Date:  2012-06-21       Impact factor: 5.588

3.  Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience.

Authors:  Chao-Yu Hsu; Steven Joniau; Raymond Oyen; Tania Roskams; Hein Van Poppel
Journal:  Eur Urol       Date:  2006-06-09       Impact factor: 20.096

Review 4.  Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy.

Authors:  Vincenzo Ficarra; Giacomo Novara; Raymond C Rosen; Walter Artibani; Peter R Carroll; Anthony Costello; Mani Menon; Francesco Montorsi; Vipul R Patel; Jens-Uwe Stolzenburg; Henk Van der Poel; Timothy G Wilson; Filiberto Zattoni; Alexandre Mottrie
Journal:  Eur Urol       Date:  2012-06-01       Impact factor: 20.096

5.  Long-term quality of life following primary treatment in men with clinical stage T3 prostate cancer.

Authors:  Shunichi Namiki; Tatsuo Tochigi; Shigeto Ishidoya; Akihiro Ito; Isao Numata; Yoichi Arai
Journal:  Qual Life Res       Date:  2010-07-31       Impact factor: 4.147

6.  Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.

Authors:  Olof Akre; Hans Garmo; Jan Adolfsson; Mats Lambe; Ola Bratt; Pär Stattin
Journal:  Eur Urol       Date:  2011-06-01       Impact factor: 20.096

7.  Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study.

Authors:  Steven Joniau; Alberto Briganti; Paolo Gontero; Giorgio Gandaglia; Lorenzo Tosco; Steffen Fieuws; Bertrand Tombal; Giansilvio Marchioro; Jochen Walz; Burkhard Kneitz; Pia Bader; Detlef Frohneberg; Alessandro Tizzani; Markus Graefen; Paul van Cangh; R Jeffrey Karnes; Francesco Montorsi; Hein Van Poppel; Martin Spahn
Journal:  Eur Urol       Date:  2014-01-25       Impact factor: 20.096

8.  Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.

Authors:  Stephen A Boorjian; R Jeffrey Karnes; Rosalia Viterbo; Laureano J Rangel; Eric J Bergstralh; Eric M Horwitz; Michael L Blute; Mark K Buyyounouski
Journal:  Cancer       Date:  2011-01-10       Impact factor: 6.860

9.  Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy.

Authors:  Ofer Yossepowitch; Scott E Eggener; Angel M Serio; Brett S Carver; Fernando J Bianco; Peter T Scardino; James A Eastham
Journal:  Eur Urol       Date:  2007-10-12       Impact factor: 20.096

10.  Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer.

Authors:  Andy C M Won; Howard Gurney; Gavin Marx; Paul De Souza; Manish I Patel
Journal:  BJU Int       Date:  2013-08       Impact factor: 5.588

View more
  1 in total

1.  Efficacy characteristics of different therapeutic modalities for locally advanced prostate cancer: a Bayesian network meta-analysis of randomized controlled trials.

Authors:  Jianxin Xue; Yi Wang; Yuxiao Zheng; Jianzhong Zhang; Feng Qi; Hong Cheng; Shuhui Si; Ran Li; Xiao Li; Zhiqiang Qin; Bin Yu; Qing Zou
Journal:  Ann Transl Med       Date:  2018-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.